Week of July 20, 2026 — curated from leading sleep research and health sources, summarized by AI.
Innovations in home sleep testing, CPAP therapy, and EEG were recognized for their design and usability in the international competition.
A study suggests snoring is not just a symptom of OSA but may actively contribute to the sleep disorder.
Researchers at the University of Texas at Austin have developed a noninvasive, wearable ultrasound patch that helps users reach REM sleep faster and maintain it longer. The NEUSLeeP device, which simultaneously monitors brain activity, shows promise as a potential therapeutic tool for managing chronic insomnia, depression, and PTSD.
Georgia Tech researchers have developed a soft, wireless wearable that uses near-infrared spectroscopy to monitor glymphatic clearance dynamics in a natural home environment. This noninvasive technology offers a cost-effective alternative to clinical MRI and polysomnography for tracking physiological changes linked to brain health during sleep.
New research from Flinders University suggests that relying on single-night sleep studies for obstructive sleep apnea may lead to misdiagnosis due to significant night-to-night variability. The study advocates for incorporating multi-night monitoring to improve diagnostic accuracy and better identify patients at higher cardiovascular risk.
A new case report demonstrates that combining the myTAP chairside titratable oral appliance with a mouth shield to enforce nasal breathing can significantly improve outcomes for patients with moderate-to-severe obstructive sleep apnea. The study highlights an 86% reduction in the apnea-hypopnea index, suggesting that minimal mandibular advancement paired with nasal patency support offers a highly effective, patient-friendly treatment approach.
The latest version of the SOMNUM software analyzes polysomnography data to automatically detect and differentiate obstructive, central, and mixed sleep apnea.
New data suggest that targeting the underlying orexin deficiency can improve a broad spectrum of narcolepsy type 1 symptoms, from daytime cognition to nighttime sleep architecture.
Phase 3 data on the orexin agonist oveporexton suggests that reducing microsleep frequency offers a more accurate reflection of real-world treatment response than traditional wakefulness tests alone.
The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.
A newly published study shows that ADX71743, a selective mGlu7 inhibitor, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models.
A recent survey reveals what sleep techs, RTs, and lab managers value most in positive airway pressure interfaces.